References
- Rayes J, Jenne CN. Platelets: bridging thrombosis and inflammation. Platelets 2021;32(3):293–294. doi:10.1080/09537104.2021.1889310
- Rosendaal FR, Raskob GE. On World Thrombosis Day. Lancet 2014;384(9955):1653–1654. doi:10.1016/S0140-6736(14)61652-4
- Flaumenhaft R, Enjyoji K, Schmaier AA. Vasculopathy in COVID-19. Blood 2022. in press. doi:10.1182/blood.2021012250
- Jiménez D, García-Sanchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, Le Mao R, Rodríguez C, Hunt BJ, Monreal M. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest 2020;159:1182–1196. doi:10.1016/j.chest.2020.11.005
- McGonagle D, De Marco G, Bridgewood C. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. J Autoimmun 2021;121:102662. doi:10.1016/j.jaut.2021.102662
- Rana A, Westein E, Niego B, Hagemeyer CE. Shear-dependent platelet aggregation: mechanisms and therapeutic opportunities. Front Cardiovas Med 2019;6:141. doi:10.3389/fcvm.2019.00141
- Smith CW. Release of α-granule contents during platelet activation. Platelets 2022;33(4):491–502. doi:10.1080/09537104.2021.1913576
- Al-Tamimi M, Qiao J, Gardiner EE. The utility of platelet activation biomarkers in thrombotic microangiopathies. Platelets 2022;33(4):503–511. doi:10.1080/09537104.2022.2026912
- Gutmann C, Mayr M. Circulating microRNAs as biomarkers and mediators of platelet activation. Platelets 2022;33(4):512–519. doi:10.1080/09537104.2022.2042236
- Babur Ö, Melrose AR, Cunliffe JM, Klimek J, Pang J, Sepp AI, Zilberman-Rudenko J, Tassi Yunga S, Zheng T, Parra-Izquierdo I, et al. Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs. Blood 2020;136:2346–2358. doi:10.1182/blood.2020005496